









市场行情
/
股票
/
nasdaq-rptx
/

Repare Therapeutics Inc

RPTX

2.140USD

-0.010-0.47%

收盘 12/19, 16:00（美东）报价延迟15分钟

91.99M总市值

亏损市盈率 TTM



Repare Therapeutics Inc

2.140

-0.010-0.47%

概览公司财务分析

概览

公司

财务

分析

关于 Repare Therapeutics Inc 公司

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

Repare Therapeutics Inc简介



公司代码RPTX

公司名称Repare Therapeutics Inc

上市日期Jun 19, 2020

CEOForte (Steve)

员工数量129

证券类型Ordinary Share

年结日Jun 19

公司地址7210 Frederick-Banting, Suite 100

城市ST-LAURENT

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Canada

邮编H4S 2A1

电话18574127018

网址https://www.reparerx.com/

公司代码RPTX

上市日期Jun 19, 2020

CEOForte (Steve)

Repare Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Michael Zinda, Ph.D.

Executive Vice President, Chief Scientific Officer

48.78K

-16.35%

Ms. Sandra Alves

Senior Vice President, Chief Accounting Officer

31.62K

+6.75%

Mr. Steve Forte

President, Chief Executive Officer, Chief Financial Officer, Director

25.28K

+8.59%

Ms. Carol Anne Schafer

Independent Director

8.00K

Mr. Thomas Civik

Independent Chairman of the Board

7.50K

Ms. Ann D. Rhoads

Independent Director

4.00K

Dr. Susan M. Molineaux, Ph.D.

Independent Director

Dr. Steven H. Stein, M.D.

Independent Director

Dr. David P. Bonita, M.D.

Independent Director

Dr. Samarth Kulkarni, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Michael Zinda, Ph.D.

Executive Vice President, Chief Scientific Officer

48.78K

-16.35%

Ms. Sandra Alves

Senior Vice President, Chief Accounting Officer

31.62K

+6.75%

Mr. Steve Forte

President, Chief Executive Officer, Chief Financial Officer, Director

25.28K

+8.59%

Ms. Carol Anne Schafer

Independent Director

8.00K

Mr. Thomas Civik

Independent Chairman of the Board

7.50K

Ms. Ann D. Rhoads

Independent Director

4.00K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月18日周四

持股股东

股东类型

持股股东

占比

BVF Partners L.P.

23.97%

Blue Owl Capital Holdings LP

7.82%

OrbiMed Advisors, LLC

7.42%

Redmile Group, LLC

3.68%

MPM Capital Inc.

2.60%

其他

54.51%

持股股东

占比

BVF Partners L.P.

23.97%

Blue Owl Capital Holdings LP

7.82%

OrbiMed Advisors, LLC

7.42%

Redmile Group, LLC

3.68%

MPM Capital Inc.

2.60%

其他

54.51%

股东类型

持股股东

占比

Hedge Fund

29.48%

Investment Advisor/Hedge Fund

10.95%

Investment Advisor

8.96%

Private Equity

7.51%

Individual Investor

0.41%

Venture Capital

0.31%

Research Firm

0.17%

Family Office

0.09%

其他

42.13%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

151

27.75M

64.60%

-9.51M

2025Q2

171

30.95M

72.17%

-10.10M

2025Q1

185

33.16M

77.30%

-8.74M

2024Q4

193

34.29M

80.67%

-8.93M

2024Q3

196

36.17M

85.09%

-7.71M

2024Q2

200

37.54M

88.44%

-7.90M

2024Q1

203

39.40M

93.34%

-5.92M

2023Q4

206

40.21M

95.29%

-816.82K

2023Q3

207

37.21M

88.27%

-2.03M

2023Q2

203

37.24M

88.48%

-4.72M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BVF Partners L.P.

10.33M

24.05%

Jun 30, 2025

Blue Owl Capital Holdings LP

3.44M

8.02%

+71.16K

+2.11%

Jun 30, 2025

OrbiMed Advisors, LLC

3.32M

7.73%

+122.13K

+3.82%

Jun 30, 2025

Redmile Group, LLC

1.59M

3.69%

-298.21K

-15.83%

Jun 30, 2025

MPM Capital Inc.

1.12M

2.61%

Jun 30, 2025

MPM BioImpact LLC

819.92K

1.91%

Jun 30, 2025

Renaissance Technologies LLC

522.86K

1.22%

+224.20K

+75.07%

Jun 30, 2025

Citadel Advisors LLC

937.49K

2.18%

Jun 30, 2025

Rangeley Capital LLC

355.29K

0.83%

+355.29K

Jun 30, 2025

Acadian Asset Management LLC

681.18K

1.59%

+40.85K

+6.38%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ARK Genomic Revolution ETF

Avantis US Small Cap Equity ETF

Avantis US Equity ETF

SPDR S&P International Small Cap ETF

ARK Genomic Revolution ETF

占比0%

Avantis US Small Cap Equity ETF

占比0%

Avantis US Equity ETF

占比0%

SPDR S&P International Small Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Repare Therapeutics Inc的前五大股东是谁？



Repare Therapeutics Inc 的前五大股东如下：
BVF Partners L.P.持有股份：10.33M，占总股份比例：24.05%。
Blue Owl Capital Holdings LP持有股份：3.44M，占总股份比例：8.02%。
OrbiMed Advisors, LLC持有股份：3.32M，占总股份比例：7.73%。
Redmile Group, LLC持有股份：1.59M，占总股份比例：3.69%。
MPM Capital Inc.持有股份：1.12M，占总股份比例：2.61%。